Cargando…

Clinical Significance of MMP7 Levels in Colorectal Cancer Patients Receiving FOLFOX4 Chemotherapy Treatment

OBJECTIVE: Various studies have shown an association between the anti-cancer drug 5-fluorouracil and matrix metalloproteinase 7 (MMP7). The expression of MMP7 in the serum of colorectal cancer patients, as well as their sensitivity to chemotherapy, were examined using the FOLFOX4 chemotherapy treatm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yeting, Wang, Leiming, Zhou, Fei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312346/ https://www.ncbi.nlm.nih.gov/pubmed/37398512 http://dx.doi.org/10.2147/IJGM.S416363

Ejemplares similares

Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy
por: Lin, Gui-Nan, et al.
Publicado: (2016)

Dynamic impact of inﬂammation-based indices in colorectal cancer patients receiving FOLFOX-based chemotherapy
por: Tao, Yong, et al.
Publicado: (2019)

High blood sugar levels but not diabetes mellitus significantly enhance oxaliplatin chemoresistance in patients with stage III colorectal cancer receiving adjuvant FOLFOX6 chemotherapy
por: Yang, I-Ping, et al.
Publicado: (2019)

Clinical Significance of has_circ_0055625 in Colon Cancer Patients Undergoing FOLFOX Chemotherapy Treatment
por: Liu, Xiuhua, et al.
Publicado: (2021)

Popliteal pseudoaneurysm after FOLFOX chemotherapy for metastatic colorectal cancer
por: Cosic, Luka, et al.
Publicado: (2019)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Modified Folfox6 as Adjuvant Chemotherapy in Vietnamese Patients With Colorectal Cancer
por: Nguyen, T. Quang, et al.
Publicado: (2019)

Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells
por: Tam, Shing-Yau, et al.
Publicado: (2023)

LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy
por: Lou, Yun-Ting, et al.
Publicado: (2015)

Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer
por: Li, Zi-Yu, et al.
Publicado: (2011)

Analysis of reduced-dose administration of oxaliplatin as adjuvant FOLFOX chemotherapy for colorectal cancer
por: Park, Dawon, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) versus FOLFOX-4 in Patients with RAS Wild-Type Metastatic Colorectal Cancer
por: Bai, Liangliang, et al.
Publicado: (2019)

Reduced Dose Intensity FOLFOX-4 as First Line Palliative Chemotherapy in Elderly Patients with Advanced Colorectal Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2005)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF
por: Xie, Honghu, et al.
Publicado: (2019)

Modified FOLFOX-6 Plus Bevacizumab Chemotherapy for Metastatic Colorectal Cancer in Patients Receiving Hemodialysis: A Report of Three Cases and Review of the Literature
por: Funasaka, Chikako, et al.
Publicado: (2019)

Prognosis of stage III colorectal carcinomas with FOLFOX adjuvant chemotherapy can be predicted by molecular subtype
por: Kwon, Yujin, et al.
Publicado: (2017)

Adjuvant Chemotherapy Using the FOLFOX Regimen in Colon Cancer
por: Jeon, Hyeong-Joon, et al.
Publicado: (2011)

Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy
por: Porcello Marrone, Luiz Carlos, et al.
Publicado: (2013)

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
por: Lacombe, Caroline, et al.
Publicado: (2023)

Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX-4 chemotherapy
por: Han, Song-Hee, et al.
Publicado: (2019)

FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis
por: Zhang, Yiyi, et al.
Publicado: (2020)

Expression and clinical significance of serum MMP-7 and PTEN levels in patients with acute myeloid leukemia
por: Wu, Jiang, et al.
Publicado: (2018)

Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
por: Cunningham, D, et al.
Publicado: (2013)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
por: Lièvre, Astrid, et al.
Publicado: (2009)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2020)

FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer
por: Guan, Yue, et al.
Publicado: (2020)

The effect and clinical efficacy of lienal polypeptide injection combined with FOLFOX chemotherapy regimen in colon cancer patients
por: Zhou, Juan, et al.
Publicado: (2016)

Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
por: Tse, Vicki C, et al.
Publicado: (2011)

Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report
por: Soon, Wai Cheong, et al.
Publicado: (2014)

Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy
por: Okada, Shunji, et al.
Publicado: (2017)

Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study
por: Le Roy, Bertrand, et al.
Publicado: (2016)

Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas
por: Masaki, T, et al.
Publicado: (2001)

Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Platelet–Lymphocyte Ratio in Patients Receiving XELOX
por: Yin, Xin, et al.
Publicado: (2020)

Clinical Efficacy of Modified Yiwei Shengyang Decoction Combined with FOLFOX4 Chemotherapy Regimen in the Treatment of Advanced Gastric Cancer and Its Effect on Tumor Marker Levels
por: Wu, Hongying, et al.
Publicado: (2022)

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
por: Lee, Suee, et al.
Publicado: (2013)

Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study
por: Qi, Fei, et al.
Publicado: (2018)

On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer
por: Moser, Tina, et al.
Publicado: (2020)

Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin
por: Faruk, Mohammed, et al.
Publicado: (2021)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
por: Jafari, Abdosaleh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_61gfbli24ok7ppf68bn9v7vjrh